CHD1 Is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer

Cancer Research

Volumn 73, Issue 9, 2013, Pages 2795-2805

  Burkhardt, Lia ^a   Fuchs, Sarah ^a   Krohn, Antje ^a   Masser, Sawinee ^a   Mader, Malte ^a   Kluth, Martina ^a   Bachmann, Frederik ^a   Huland, Hartwig ^a   Steuber, Thomas ^a   Graefen, Markus ^a   Schlomm, Thorsten ^a   Minner, Sarah ^a   Sauter, Guido ^a   Sirma, Hüseyin ^a   Simon, Ronald ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CHROMODOMAIN HELICASE DNA BINDING PROTEIN 1; DNA BINDING PROTEIN; MEMBRANE PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTATE SPECIFIC ANTIGEN; REPULSIVE GUIDANCE MOLECULE B; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR NKX3.1; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; CHD1 GENE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOME 5Q; ERG GENE; FLUORESCENCE IN SITU HYBRIDIZATION; FOXO1 GENE; GENE DELETION; GENE EXPRESSION REGULATION; GENE FUSION; GENE INACTIVATION; GENE MAPPING; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; NKX3-1 GENE; ONCOGENE; PPARGAMMA GENE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 5; DNA HELICASES; DNA-BINDING PROTEINS; GENE DELETION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REARRANGEMENT; GENES, TUMOR SUPPRESSOR; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANS-ACTIVATORS; TRANSLOCATION, GENETIC;

EID: 84877747485     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-1342     Document Type: Article

References (36)

1. Rubin MA, Maher CA, Chinnaiyan AM. Common gene rearrangements in prostate cancer. J Clin Oncol 2011;29:3659-68.
2. Barbieri CE, Demichelis F, Rubin MA. Molecular genetics of prostate cancer: emerging appreciation of genetic complexity. Histopathology 2012;60:187-98.
3. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-8.
4. Gao X, Zacharek A, Grignon D, Liu H, Sakr W, Porter A, et al. Highfrequency of loss of expression and allelic deletion of the apc and mcc genes in human prostate-cancer. Int J Oncol 1995;6:111-7.
5. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
6. Sun J, Liu W, Adams TS, Li X, Turner AR, Chang B, et al. DNA copy number alterations in prostate cancers: a combined analysis of published CGH studies. Prostate 2007;67:692-700.
7. Lapointe J, Li C, Giacomini CP, Salari K, Huang S, Wang P, et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 2007;67:8504-10.
8. Liu W, Lindberg J, Sui G, Luo J, Egevad L, Li T, et al. Identification of novel CHD1-associated collaborative alterations of genomic structure and functional assessment of CHD1 in prostate cancer. Oncogene 2012;31:3939-48.
9. Huang S, Gulzar ZG, Salari K, Lapointe J, Brooks JD, Pollack Jr. Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness. Oncogene 2012;31:4164-70.
10. Gaspar-Maia A, Alajem A, Polesso F, Sridharan R, Mason MJ, Heidersbach A, et al. Chd1 regulates open chromatin and pluripotency of embryonic stem cells. Nature 2009;460:863-8.
11. Nagarajan P, Onami TM, Rajagopalan S, Kania S, Donnell R, Venkatachalam S. Role of chromodomain helicase DNA-binding protein 2 in DNA damage response signaling and tumorigenesis. Oncogene 2009; 28:1053-62.
12. Kim MS, Chung NG, Kang MR, Yoo NJ, Lee SH. Genetic and expressional alterations of CHD genes in gastric and colorectal cancers. Histopathology 2011;58:660-8.
13. Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A, Jones D, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010;463:184-90.
14. Bagchi A, Papazoglu C, Wu Y, Capurso D, Brodt M, Francis D, et al. CHD5 is a tumor suppressor at human 1p36. Cell 2007;128:459-75.
15. Bagchi A, Mills AA. The quest for the 1p36 tumor suppressor. Cancer Res 2008;68:2551-6.
16. Menon T, Yates JA, Bochar DA. Regulation of androgen-responsive transcription by the chromatin remodeling factor CHD8. Mol Endocrinol 2010;24:1165-74.
17. Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, et al. lntegrative genomic analyses reveal an androgendriven somatic alteration landscape in early-onset prostate cancer. Cancer Cell 2013;23:159-70.
18. Minner S, Jessen B, Stiedenroth L, Burandt E, Kollermann J, Mirlacher M, et al. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res 2010;16:1553-60.
19. Mader M, Simon R, Steinbiss S, Kurtz S. FISH Oracle: a web server for flexible visualization of DNA copy number data in a genomic context. J Clin Bioinforma 2011;1:20.
20. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A 2007;104:20007-12.
21. Sellers WR, Novitch BG, Miyake S, Heith A, Otterson GA, Kaye FJ, et al. Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth. Genes Dev 1998;12:95-106.
22. Ramaswamy S, Nakamura N, Vazquez F, Batt DB, Perera S, Roberts TM, et al. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 1999;96: 2110-5.
23. Cuchet D, Sykes A, Nicolas A, Orr A, Murray J, Sirma H, et al. PML isoforms I and II participate in PML-dependent restriction of HSV-1 replication. J Cell Sci 2011;124:280-91.
24. Everett RD, Parada C, Gripon P, Sirma H, Orr A. Replication of ICP0- null mutant herpes simplex virus type 1 is restricted by both PML and Sp100. J Virol 2008;82:2661-72.
25. Sirma H, Kumar M, Meena JK, Witt B, Weise JM, Lechel A, et al. The promoter of human telomerase reverse transcriptase is activated during liver regeneration and hepatocyte proliferation. Gastroenterology 2011;141:326-37.
26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-8.
27. Berger MF, Lawrence MS, Demichelis F, Drier Y, Cibulskis K, Sivachenko AY, et al. The genomic complexity of primary human prostate cancer. Nature 2010;470:214-20.
28. Nijhawan D, Zack TI, Ren Y, Strickland MR, Lamothe R, Schumacher SE, et al. Cancer vulnerabilities unveiled by genomic loss. Cell 2012; 150:842-54.
29. Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, et al. Crucial role of p53-dependent cellular senescence in suppression of Ptendeficient tumorigenesis. Nature 2005;436:725-30.
30. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012; 44:685-9.
31. Grasso CS,WuYM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012;487:239-43.
32. Demichelis F, Setlur SR, Beroukhim R, Perner S, Korbel JO, Lafargue CJ, et al. Distinct genomic aberrations associated with ERG rearranged prostate cancer. Genes Chromosomes Cancer 2009;48: 366-80.
33. Lin C, Yang L, Tanasa B, Hutt K, Ju BG, Ohgi K, et al. Nuclear receptorinduced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 2009;139:1069-83.
34. Mani RS, Tomlins SA, Callahan K, Ghosh A, Nyati MK, Varambally S, et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science 2009;326:1230.
35. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 1998;58:2720-3.
36. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTORcomplex. Science 2005;307: 1098-101.